1.Comparison of therapeutic efficacy between recombinant human brain natriuretic peptide and sodium nitroprusside in treatment of acute attack of chronic heart failure
Jingping WANG ; Yuean ZHANG ; Huixian WANG ; Jin DONG ; Xiaoxia ZENG ; Jianling WANG ; Haozhou ZHANG ; Bao LI
Chinese Journal of Geriatrics 2011;30(8):643-646
Objective To compare the curative effects between recombinant human brain natriuretic peptide (rhBNP) and sodium nitroprusside in treatment of the acute attack of elderly patients with chronic heart failure (CHF), and probe the impacts of rhBNP on the heart function,serum B-type natriuretic peptide (BNP), norepinephrine (NE), endothelin 1 (ET-1) and antidiuretic hormone (ADH) levels. Methods The 89 patients aged 65-85 years at acute attack stage of CHF were randomized into two therapy groups: rhBNP group (n= 47) and sodium nitroprusside group (n=42). The clinical effects, heart function, serum BNP, NE, ET-1 and ADH changes were observed before and after the treatment. Results After 24 hours of treatment, the efficacy rate and total effective rate were higher in rhBNP group than in sodium nitroprusside group (51.1% vs. 26.2 %,95.7% vs. 66. 7%, respectively, P<0. 05 and P<0. 01), and non-efficacy rate in rhBNP group was lower (4.3% vs. 33. 3%, P<0. 01). There was one death case in rhBNP group and three in sodium nitroprusside group. In rhBNP group, left ventricular ejection fraction values increased after 2 weeks of treatment [(46.2± 9.5)% vs. (38.1 ±6.0)%], P<0.05. Serum BNP level significantly decreased in rhlBNP group than in sodium nitroprusside group after 2 weeks of treatment (P<0.05).In rhBNP group, serum BNP and NE levels decreased 24 hours and 2 weeks after treatment (P<0. 01) and the levels furtherly reduced after 2 weeks (P<0.01). Serum ET-1 level decreased in rhBNP group than in sodium nitroprusside group 2 weeks after treatment (P<0.05). In rhBNP group, there was no significant difference in serum ET-1 level between baseline and 24 hours after treatment (P> 0. 05), but the ET-1 level decreased 2 weeks after treatment as compared with 24 hours after treatment (P<0.01). There were no significant differences between the two groups before and after treatment (P>0.05). Incidences of headache and hypotension were lower in rhBNP group than in sodium nitroprusside group (4.3% vs. 19.0%, 14.9% vs. 23.8%, both P<0.05),Conclusions RhBNP can be safely and effectively used for acute attack of CHF.
2.Phyllanthi Fructus: A modal medicinal and food homologous item in quality evaluation.
Gefei LI ; Yurou JIANG ; Dingkun ZHANG ; Li HAN ; Taigang MO ; Sanhu FAN ; Haozhou HUANG ; Junzhi LIN
Chinese Herbal Medicines 2023;15(3):360-368
Phyllanthi Fructus is a highly unique medicine and food homologous item, which exhibits distinctive flavor, notable nutritional value, and abundant pharmacological activity. It has enormous potential in the creation of health products and pharmaceuticals. However, due to the unique laws of quality formation and transfer of Phyllanthi Fructus, its appearance, shape, chemical compositions, nutrients, and sensory flavors are frequently greatly influenced by botanical resources, the processing and storage conditions. As a result, the current quality evaluation model is difficult to meet the needs of Phyllanthi Fructus as a medicine and food homologous item in the development of diversified products. This paper constructs the hierarchical utilization mode of Phyllanthi Fructus based on its unique quality formation and transmission laws, explores the quality evaluation model for food-oriented use and medicinal-oriented use, respectively, and systematically describes the quality evaluation idea under diversified application scenarios. This paper aims to serve as a reference for the construction of a quality evaluation model suitable for the medicine and food homologous item of Phyllanthi Fructus.
3.Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies.
Hu DONG ; Pan LIU ; Manyuan BAI ; Kang WANG ; Rui FENG ; Dandan ZHU ; Yao SUN ; Suyu MU ; Haozhou LI ; Michiel HARMSEN ; Shiqi SUN ; Xiangxi WANG ; Huichen GUO
Protein & Cell 2022;13(6):446-453